AbbVie Ebitda from 2010 to 2024

ABBV Stock  USD 181.77  1.16  0.63%   
AbbVie EBITDA yearly trend continues to be fairly stable with very little volatility. EBITDA will likely drop to about 13.5 B in 2024. During the period from 2010 to 2024, AbbVie EBITDA regression line of quarterly data had mean square error of 32456732 T and geometric mean of  10,647,865,902. View All Fundamentals
 
EBITDA  
First Reported
2011-03-31
Previous Quarter
7.1 B
Current Value
4.9 B
Quarterly Volatility
2.2 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AbbVie financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AbbVie's main balance sheet or income statement drivers, such as Depreciation And Amortization of 9.1 B, Interest Expense of 1.1 B or Selling General Administrative of 7.8 B, as well as many indicators such as Price To Sales Ratio of 3.39, Dividend Yield of 0.0289 or PTB Ratio of 17.2. AbbVie financial statements analysis is a perfect complement when working with AbbVie Valuation or Volatility modules.
  
Check out the analysis of AbbVie Correlation against competitors.

Latest AbbVie's Ebitda Growth Pattern

Below is the plot of the Ebitda of AbbVie Inc over the last few years. It is AbbVie's EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in AbbVie's overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

AbbVie Ebitda Regression Statistics

Arithmetic Mean12,793,588,503
Geometric Mean10,647,865,902
Coefficient Of Variation65.66
Mean Deviation6,494,411,270
Median10,573,000,000
Standard Deviation8,400,720,276
Sample Variance70572101.2T
Range27.2B
R-Value0.76
Mean Square Error32456732T
R-Squared0.57
Significance0
Slope1,421,859,824
Total Sum of Squares988009416.3T

AbbVie Ebitda History

202413.5 B
202317.3 B
202231.4 B
202128.3 B
202021.1 B
201913.8 B
20188.1 B

About AbbVie Financial Statements

AbbVie investors use historical fundamental indicators, such as AbbVie's Ebitda, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in AbbVie. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
EBITDA17.3 B13.5 B

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for AbbVie Stock Analysis

When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.